by Kathrin Kottke, University of Münster Credit: Blood Advances (2023). DOI: 10.1182/bloodadvances.2023011076Decisions on treatment for patients with acute myeloid leukemia (AML)—a highly aggressive form of leukemia—are based, among other things, on a series of certain genetic features of the disease; but at the time when a diagnosis is made, this information is not available. Evidence of...
